These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 3865715)

  • 1. The isolation of natural killer (NK)-resistant variants of the K562 cell line by mutagenesis and selection with antibodies which inhibit NK cell-mediated lysis.
    Werkmeister JA; Triglia T; Burns GF
    Cell Immunol; 1985 Apr; 92(1):123-33. PubMed ID: 3865715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-idiotype antibodies to the 9.1C3 blocking antibody used to probe the lethal hit stage of NK cell-mediated cytolysis.
    Werkmeister JA; Burns GF; Triglia T
    J Immunol; 1984 Sep; 133(3):1385-90. PubMed ID: 6611373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of human natural killer recognition demonstrated by cloned effector cells and differential blocking of cytotoxicity with monoclonal antibodies.
    Pawelec G; Newman W; Schwulera U; Wernet P
    Cell Immunol; 1985 Apr; 92(1):31-40. PubMed ID: 3865716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K562 killing by K, IL 2-responsive NK, and T cells involves different effector cell post-binding trigger mechanisms.
    Shanahan F; Brogan MD; Newman W; Targan SR
    J Immunol; 1986 Jul; 137(2):723-6. PubMed ID: 3487579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
    Burns GF; Triglia T; Werkmeister JA
    J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.
    Bolhuis RL; Roozemond RC; van de Griend RJ
    J Immunol; 1986 Jun; 136(11):3939-44. PubMed ID: 3084649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies.
    van de Griend RJ; Giphart MJ; Van Krimpen BA; Bolhuis RL
    J Immunol; 1984 Sep; 133(3):1222-9. PubMed ID: 6205072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences of K562 leukemia cell clones in the pattern of monoclonal antibody binding and NK cell susceptibility.
    Hering S; Böttger V; Jantscheff P; Micheel B
    Biomed Biochim Acta; 1986; 45(5):673-9. PubMed ID: 3463302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel antigenic cell surface protein associated with T200 is involved in the post-activation stage of human NK cell-mediated lysis.
    Burns GF; Werkmeister JA; Triglia T
    J Immunol; 1984 Sep; 133(3):1391-6. PubMed ID: 6379048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing.
    Perl A; Looney RJ; Ryan DH; Abraham GN
    J Immunol; 1986 Jun; 136(12):4714-20. PubMed ID: 3011902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
    Bishop GA; Marlin SD; Schwartz SA; Glorioso JC
    J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of target cell recognition by natural killer cells: characterization of a novel triggering molecule restricted to CD3- large granular lymphocytes.
    Frey JL; Bino T; Kantor RR; Segal DM; Giardina SL; Roder J; Anderson S; Ortaldo JR
    J Exp Med; 1991 Dec; 174(6):1527-36. PubMed ID: 1720812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2).
    Ciccone E; Pende D; Viale O; Than A; Di Donato C; Orengo AM; Biassoni R; Verdiani S; Amoroso A; Moretta A
    J Exp Med; 1992 Oct; 176(4):963-71. PubMed ID: 1328466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells.
    Schmidt RE; Bartley G; Levine H; Schlossman SF; Ritz J
    J Immunol; 1985 Aug; 135(2):1020-5. PubMed ID: 3924996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a human natural killer cell target cell antigen with monoclonal antibodies.
    Harris DT; Jaso-Friedmann L; Devlin RB; Koren HS; Evans DL
    J Immunol; 1989 Jul; 143(2):727-35. PubMed ID: 2738407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
    Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K562 cells induced to differentiate by phorbol ester tumor promotors resist NK lysis.
    Dokhelar MC; Garson D; Wakasugi H; Tabilio A; Testa U; Vainchenker W; Tursz T
    Cell Immunol; 1984 Sep; 87(2):389-99. PubMed ID: 6205768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression.
    Nishimura M; Mitsunaga S; Akaza T; Mitomi Y; Tadokoro K; Juji T
    Immunology; 1994 Sep; 83(1):75-80. PubMed ID: 7821970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.